Celldex Therapeutics (CLDX) Net Income towards Common Stockholders (2010 - 2026)

Celldex Therapeutics' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$85.9 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 59.68% year-over-year to -$85.9 million in Q1 2026; TTM through Mar 2026 was -$326.8 million, a 82.67% decrease from a year earlier, with the FY2025 full-year figure at -$661.6 million, down 318.97% from the prior year.
• Net Income towards Common Stockholders rose to -$85.9 million in Q1 2026 per CLDX's latest filing, from -$109.6 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$23.0 million in Q1 2022 and bottomed at -$109.6 million in Q4 2025.
• The 5-year median for Net Income towards Common Stockholders is -$38.3 million (2023), against an average of -$46.6 million.
• Across the five-year window, Net Income towards Common Stockholders slumped 169.23% in 2022 and grew 15.28% in 2023, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$26.5 million in 2022, then tumbled by 63.5% to -$43.3 million in 2023, then fell by 8.83% to -$47.1 million in 2024, then tumbled by 132.59% to -$109.6 million in 2025, then increased by 21.63% to -$85.9 million in 2026.
• Per Business Quant, the three latest CLDX Net Income towards Common Stockholders figures stand at -$85.9 million (Q1 2026), -$109.6 million (Q4 2025), and -$67.0 million (Q3 2025).